We are thrilled to announce that GSK has successfully raised $245 million in our latest funding round, a significant milestone that underscores our unwavering commitment to uniting science, technology, and talent in the fight against disease. This substantial investment will enable us to accelerate our innovative research and development efforts, ultimately leading to the discovery of cutting-edge therapies and vaccines that can profoundly impact global health. With a vision to create a healthier future for all, GSK is harnessing the power of advanced technologies and collaboration among the brightest minds in the industry to tackle some of the world鈥檚 most pressing health challenges. This funding will bolster our current projects, enhance our manufacturing capabilities, and expand our global reach, ensuring that life-saving solutions are accessible to those in need. We are grateful for the trust placed in us by our investors and remain steadfast in our mission to deliver transformative healthcare solutions. As we move forward, we invite all stakeholders to engage with us on this exciting journey, and we encourage everyone to stay updated on our progress by following our community guidelines available at https://gsk.to/socialmedia. Together, we can get ahead of disease and pave the way for a healthier tomorrow.
Breaking News: GSK Secures $245M in Series A Funding to Advance Disease-Prevention Technologies
Recently funded 路 $245.0M Series aPharmaceutical Manufacturing
Get the full GSK company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Empirical Security
Empirical builds mathematical models for security data. We maintain the world鈥檚 most advanced global models for cybersecurity, and we build local models that respond to your enterprise鈥檚 specific context and threat landscape.
$25.0M Series a
today
Silicon Microgravity Ltd
Silicon Microgravity Limited (SMG) is a technology company focused on the inertial navigation and gravity markets. Over 10 years of research and development, first at Cambridge University's Nanoscience Department and then carried on inside SMG, has gone in to our resonant MEMS technology. Today SMG's team of scientists and engineers are based in our Technology Centre in Waterbeach, just north of Cambridge, England. SMG focuses on two markets. > Inertial navigation where our MEMS accelerometers and gyroscopes provide higher accuracy, smaller form factor and lower cost compared to existing sensors. > Gravity sensing where our MEMS gravimeters offer robust, compact solutions for gravity surveys and alternative navigation.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | Empirical Security United States | Series a | $25.0M | today |
| 2 |  Trellis Bioscience Inc. United States | Series a | $9.0M | today |
